The Utility of the Platelet-Lymphocyte Ratio for Predicting No Reflow in Patients With ST-Segment Elevation Myocardial Infarction

Basit Öğe Kaydı
dc.contributor.authorYildiz, Abdulkadir
dc.contributor.authorYuksel, Murat
dc.contributor.authorOylumlu, Mustafa
dc.contributor.authorPolat, Nihat
dc.contributor.authorAkyuz, Abdurrahman
dc.contributor.authorAcet, Halit
dc.contributor.authorAydin, Mesut
dc.date.accessioned2024-04-24T17:14:39Z
dc.date.available2024-04-24T17:14:39Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe aim of the study was to evaluate the utility of the preprocedural platelet-lymphocyte ratio (PLR) for predicting no reflow in patients undergoing primary percutaneous intervention (PCI) for the treatment of ST-segment elevation myocardial infarction. The thrombolysis in myocardial infarction (TIMI) flow grades of 287 patients treated with primary PCI were assessed retrospectively. Patients were divided into 3 tertiles based upon preprocedural PLR. Pre- and postprocedural TIMI flow grades were evaluated. No reflow developed in 6, 14, and 43 patients in the lower, middle, and higher tertiles, respectively (P < .001). After multivariate analysis, PLR remained a significant predictor of no reflow together with neutrophil-lymphocyte ratio (NLR). A cutoff value of 160 for PLR and 5.9 for NLR predicted no reflow with sensitivities and specificities of 75% and 71% and 74% and 70%, respectively. In conclusion, high preprocedural PLR and NLR levels are significant and independent predictors of no reflow in patients undergoing primary PCI.en_US
dc.description.sponsorshipDicle University DUBAPen_US
dc.description.sponsorshipWe are grateful to Dicle University DUBAP for their sponsorship about English editing of this manuscript.en_US
dc.identifier.doi10.1177/1076029613519851
dc.identifier.endpage228en_US
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.issue3en_US
dc.identifier.pmid24431380
dc.identifier.scopus2-s2.0-84924911417
dc.identifier.scopusqualityQ2
dc.identifier.startpage223en_US
dc.identifier.urihttps://doi.org/10.1177/1076029613519851
dc.identifier.urihttps://hdl.handle.net/11468/18122
dc.identifier.volume21en_US
dc.identifier.wosWOS:000350492800004
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofClinical and Applied Thrombosis-Hemostasis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPrimary Percutaneous Coronary Interventionen_US
dc.subjectAcute St-Segment Elevation Myocardial Infarctionen_US
dc.subjectPlatelet To Lymphocyte Ratioen_US
dc.subjectNo Reflowen_US
dc.titleThe Utility of the Platelet-Lymphocyte Ratio for Predicting No Reflow in Patients With ST-Segment Elevation Myocardial Infarctionen_US
dc.titleThe Utility of the Platelet-Lymphocyte Ratio for Predicting No Reflow in Patients With ST-Segment Elevation Myocardial Infarction
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu